Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib and Romiplostim N01 in Primary Immune Thrombocytopenia (ORBIT)
NCT07400250Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in primary immune thrombocytopenia (ITP), sponsored by Peking Union Medical College Hospital. Primary endpoint: 24-Week Sustained Platelet Response Rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07400250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400250.